Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
$1.41
-7.2%
$1.66
$1.14
$42.40
$3.92M-2.99521,395 shs127,712 shs
Avinger, Inc. stock logo
AVGR
Avinger
$0.47
$0.47
$0.36
$1.93
$1.57M1.291.35 million shsN/A
Bellevue Life Sciences Acquisition Corp. stock logo
BLAC
Bellevue Life Sciences Acquisition
$1.35
-2.9%
$1.34
$3.01
$13.40
$5.46M-0.0821,829 shs120,923 shs
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
$9.08
-1.2%
$8.17
$5.01
$54.95
$5.36M1.47137,739 shs2,795 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
0.00%-29.85%-4.73%-12.42%-88.98%
Avinger, Inc. stock logo
AVGR
Avinger
0.00%0.00%0.00%0.00%-72.84%
Bellevue Life Sciences Acquisition Corp. stock logo
BLAC
Bellevue Life Sciences Acquisition
0.00%0.00%-3.57%-30.77%-87.49%
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
0.00%-2.05%+2.95%+29.39%-55.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
3.0351 of 5 stars
3.52.00.00.03.01.71.3
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/AN/AN/AN/AN/AN/A
Bellevue Life Sciences Acquisition Corp. stock logo
BLAC
Bellevue Life Sciences Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
0.5191 of 5 stars
0.04.00.00.00.00.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
3.00
Buy$16.501,070.21% Upside
Avinger, Inc. stock logo
AVGR
Avinger
0.00
N/AN/AN/A
Bellevue Life Sciences Acquisition Corp. stock logo
BLAC
Bellevue Life Sciences Acquisition
0.00
N/AN/AN/A
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AVGR, AMIX, BLAC, and QNRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2025
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$5.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
N/AN/AN/AN/A$3.29 per shareN/A
Avinger, Inc. stock logo
AVGR
Avinger
$7.65M0.21N/AN/A($4.53) per share-0.10
Bellevue Life Sciences Acquisition Corp. stock logo
BLAC
Bellevue Life Sciences Acquisition
N/AN/AN/AN/AN/AN/A
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
N/AN/AN/AN/A$35.47 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
-$11.41M-$7.47N/AN/AN/AN/A-174.70%-133.35%N/A
Avinger, Inc. stock logo
AVGR
Avinger
-$18.32M-$11.06N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)
Bellevue Life Sciences Acquisition Corp. stock logo
BLAC
Bellevue Life Sciences Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
-$8.96M-$48.81N/AN/AN/AN/A-148.97%-77.23%8/14/2025 (Estimated)

Latest AVGR, AMIX, BLAC, and QNRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
N/A-$0.74N/A-$0.74N/AN/A
5/13/2025Q1 2025
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
-$3.85-$6.50-$2.65-$6.50N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
N/AN/AN/AN/AN/A
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/AN/AN/A
Bellevue Life Sciences Acquisition Corp. stock logo
BLAC
Bellevue Life Sciences Acquisition
N/AN/AN/AN/AN/A
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
N/A
5.63
5.63
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/A
Bellevue Life Sciences Acquisition Corp. stock logo
BLAC
Bellevue Life Sciences Acquisition
N/AN/AN/A
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
N/A
2.57
2.57

Institutional Ownership

CompanyInstitutional Ownership
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
10.78%
Avinger, Inc. stock logo
AVGR
Avinger
18.30%
Bellevue Life Sciences Acquisition Corp. stock logo
BLAC
Bellevue Life Sciences Acquisition
55.30%
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
8.63%

Insider Ownership

CompanyInsider Ownership
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
32.40%
Avinger, Inc. stock logo
AVGR
Avinger
42.80%
Bellevue Life Sciences Acquisition Corp. stock logo
BLAC
Bellevue Life Sciences Acquisition
33.67%
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
12.78 million1.88 millionN/A
Avinger, Inc. stock logo
AVGR
Avinger
703.31 million1.89 millionNot Optionable
Bellevue Life Sciences Acquisition Corp. stock logo
BLAC
Bellevue Life Sciences Acquisition
N/A4.04 million2.68 millionNot Optionable
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
4590,000566,000Not Optionable

Recent News About These Companies

Quoin Pharmaceuticals, Ltd. (QNRX) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Autonomix Medical stock logo

Autonomix Medical NASDAQ:AMIX

$1.41 -0.11 (-7.24%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$1.43 +0.02 (+1.42%)
As of 07/3/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

Avinger stock logo

Avinger NASDAQ:AVGR

$0.47 0.00 (0.00%)
As of 07/1/2025

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.

Bellevue Life Sciences Acquisition stock logo

Bellevue Life Sciences Acquisition NASDAQ:BLAC

$1.35 -0.04 (-2.88%)
As of 07/3/2025

Bellevue Life Sciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry. The company was incorporated in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.

Quoin Pharmaceuticals stock logo

Quoin Pharmaceuticals NASDAQ:QNRX

$9.08 -0.11 (-1.20%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$9.07 -0.01 (-0.06%)
As of 07/3/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.